GABA-Producing Bacteria for Gut Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for increasing GABA levels in humans, such as through GABA-enriched food products, face challenges in efficiently delivering sufficient amounts, and there is a lack of identified human GIT-derived bacteria capable of producing GABA from dietary glutamate.
Innovation Solution
Discovery and characterization of specific strains of bacteria, including Lactobacillus brevis DPC6108, Bifidobacterium dentium DPC6333, Bifidobacterium adolescentis DPC6044, and Bifidobacterium infantis UCC35624, which can efficiently convert glutamate into GABA, offering a probiotic solution for GABA production within the human gut.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If GABA-enriched food products are used to increase GABA levels in humans, then GABA delivery is achieved, but the amount of active agent required is excessively large (1-2g per day)
Solution Approach 1:
The patent employs GABA-producing bacteria that can synthesize GABA autonomously from dietary glutamate within the human gastrointestinal tract. The bacteria self-generate the active agent (GABA) using naturally occurring substrates (glutamate) from the diet, eliminating the need to externally add large amounts of GABA to food products. This self-service mechanism transforms the approach from passive supplementation to active in-situ production.
2Quantity of substance
If conventional GABA supplementation methods are used, then GABA levels can be increased, but the complexity and cost of delivering sufficient active agent increases significantly
Solution Approach 1:
The patent introduces GABA-producing bacteria as an intermediary system between dietary glutamate and the host. These bacteria act as living factories that convert glutamate to GABA through the gad gene-encoded glutamate decarboxylase enzyme. This intermediary approach simplifies the delivery system by using a biological conversion pathway rather than direct supplementation, reducing the complexity of formulating and delivering high concentrations of GABA.
3Productivity
If GABA is produced through dietary supplementation, then GABA levels increase, but the efficiency of conversion from glutamate to GABA is insufficient without specialized bacteria
Solution Approach 1:
The patent utilizes bacteria with modified or optimized parameters for GABA production, specifically those possessing high activity of the gad gene (glutamate decarboxylase). These bacteria have enhanced enzymatic parameters that enable efficient conversion of glutamate to GABA under physiological conditions. The selection and characterization of specific strains (e.g., Lactobacillus brevis DPC6108, Bifidobacterium dentium DPC6333) with optimized biochemical parameters maximizes GABA production efficiency from dietary glutamate.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bacteria strains demonstrate high conversion rates of monosodium glutamate to GABA in vitro and show clinically significant anxiolytic effects in animal behavioral tests, providing a viable method for increasing GABA levels and addressing anxiety and other health indications.
Implementation Method 1
GABA is produced primarily from the irreversible α-decarboxylation of L-glutamate by the enzyme glutamate decarboxylase (GAD), a pyridoxal 5'-phosphate (PLP)-dependant enzyme
Data Source
Figure 1~2
AI summary
Isolated bacteria are described that are characterised by being culturable, derived from a human neonatal gastrointestinal tract, and having the ability to produce gamma-aminobutyric acid. Also described is the use of the GABA-producing bacteria in the treatment or regulation of cardiovascular function, mood disturbance, anxiety, stress, pain and proliferative disorders.